EGCG Derivative Antibacterial Agent with Acyl Groups
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial agents based on epigallocatechin gallate (EGCG) have limitations in terms of antibacterial effectiveness and stability, necessitating the development of novel derivatives with enhanced safety and efficacy.
Innovation Solution
The development of EGCG derivatives with specific acyl groups, such as octanoyl, lauroyl, palmitoyl, and stearoyl groups, which are introduced via an enzyme reaction using lipases, to create compounds with improved antibacterial properties and metabolic stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EGCG is used as an antibacterial agent, then safety is improved because it is naturally derived, but antibacterial effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of EGCG through acylation at specific positions (R1-R6) with various acyl groups. This structural modification changes the physical and chemical parameters of the molecule, enhancing its antibacterial effectiveness while preserving the safety benefits of the natural EGCG core structure.
Solution Approach 2:
The patent creates composite molecular structures by combining EGCG with acyl groups to form EGCG derivatives. These composite structures integrate the safety properties of natural EGCG with the enhanced antibacterial characteristics of the acyl-modified structure, achieving both safety and effectiveness.
2Object-generated harmful factors
If EGCG derivatives with acyl groups are introduced to enhance antibacterial activity, then antibacterial effectiveness is improved, but metabolic stability may be compromised
Solution Approach 1:
The patent applies local quality by selectively introducing acyl groups at specific positions (R1-R6) on the EGCG molecule rather than uniform modification throughout. This localized modification allows optimization of antibacterial activity at specific sites while preserving the metabolic stability of the overall molecular structure.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying the type, position, and number of acyl groups to optimize the balance between antibacterial activity and metabolic stability. Different acyl groups and substitution patterns are evaluated to achieve the desired parameter optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These EGCG derivatives demonstrate enhanced antibacterial activity against various bacterial strains, including MRSA, with increased metabolic stability and safety, making them suitable for pharmaceutical applications.
Implementation Method 1
The development of EGCG derivatives with specific acyl groups, such as octanoyl, lauroyl, palmitoyl, and stearoyl groups, which are introduced via an enzyme reaction using lipases
Data Source
AI summary
The present invention provides an epigallocatechin gallate derivative (EGCG derivative) that has excellent safety and antibacterial properties. An epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is used as an antibacterial agent. In the formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of the R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.